JPMorgan ups SpringWorks target, adds to Analyst Focus List

JPMorgan raised the firm’s price target on SpringWorks Therapeutics to $74 from $68 and keeps an Overweight rating on the shares. The analyst also added the shares to the firm’s Analyst Focus List. Ogsiveo patient adds in desmoid tumors will come from incidence, actively treated, as well as, “wait and watch” populations in the near-term, the analyst tells investors in a research note. The firm says physician feedback suggests Ogsiveo is a “treatment paradigm changing product.”